Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): Single institution experience in 600 patients

Clinical and Translational Oncology

Volumn 14, Issue 8, 2012, Pages 613-618

  Jeremić, Branislav ^a,b   Miličić, Biljana ^a   Milisavljevic, Slobodan ^a  

^a University Hospital   (Serbia)

^b Institute of Pulmonary Diseases of Vojvodina   (Serbia)

Author keywords

Chemotherapy; Locally advanced non small cell lung cancer; Radiation therapy; Side effects

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PACLITAXEL;

ARTICLE; BONE DISEASE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; ESOPHAGUS DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERFRACTIONATED RADIATION THERAPY; KARNOFSKY PERFORMANCE STATUS; LUNG DISEASE; LUNG NON SMALL CELL CANCER; RADIATION DOSE; RETROSPECTIVE STUDY; SKIN DISEASE; STOMACH DISEASE; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DOSE FRACTIONATION; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE;

EID: 84865730567     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0848-5     Document Type: Article

References (38)

1. Trovo MG, Minatel E, Veronesi A et al (1990) Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study. Cancer 65:400-404
2. Morton RF, Jett JR, McGinnis WL et al (1991) Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Int Med 115:681-686
3. Blanke C, Ansari R, Mantravadi R et al (1995) Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable nonsmall-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 13:1425-1429
4. Schaake-Konig C, van der Bogaert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. New Engl J Med 326:524-530
5. Curran WJ Jr, Scott C, Langer C et al (2000) Phase III comparison of sequential Vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 19:484a (Abstr.)
6. Furuse K, Nishikawa H, Takada Y et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699 (Pubitemid 29415225)
7. Aupérin A, Le Péchoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181-2190
8. Liang H-Y, Zhou H, Li XL, Yin ZH, Guan P, Zhou BS (2010) Chemo-radiotherapy for advanced non-small cell lung cancer: concurrent or sequential? It's no longer the question: a systematic review. Int J Cancer 127:718-728
9. Lee JS, Scott C, Komaki R et al (1996) Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation Therapy Oncology Group protocol 91-06. J Clin Oncol 14:1055-1064 (Pubitemid 26105509)
10. Komaki R, Scott C, Ettinger D et al (1997) Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 38:149-155 (Pubitemid 27270955)
11. Byhardt RW, Scott CB, Ettinger DS et al (1995) Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15. Cancer 75:2337-2344
12. Jeremić B, Shibamoto Y, Acimovic L, Djuric L (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458
13. Jeremić B, Shibamoto Y, Acimovic L, Milisavljevic S (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14:1065-1070 (Pubitemid 26105510)
14. Jeremić B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Milisavljevic S (1998) Concurrent radiochemotherapy for patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II study. Int J Radiat Oncol Biol Phys 42:1091-1096 (Pubitemid 29004153)
15. Jeremić B, Shibamoto Y, Acimovic LJ et al (2001) Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without week-end carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 50:19-25
16. Jeremić B, Milicic B, Acimovic L, Milisavljevic S (2005) Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II study. J Clin Oncol 23:1144-1151 (Pubitemid 46202270)
17. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Treatment and Research of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346
18. Movsas B, Scott C, Sause W et al (1999) The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of Radiation Therapy Oncology Grpup (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 45:1143-1149
19. Scott CB, Movsas B, Sause W et al (1997) Intensified treatment increases survival in patients with non-small cell lung cancer (NSCLC) at what price? A quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemo-radiation studies. Qual Life Res 6:718
20. Byhardt RW, Scott C, Sause WT et al (1998) Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42:469-478 (Pubitemid 28501093)
21. Choy H, Akerley W, Safran H et al (1998) Multiinstitutional phase II trial of paclitaxel, carboplatin and concurrent radiation therapy for locally advanced nonsmall cell lung cancer. J Clin Oncol 16:3316-3322 (Pubitemid 28481627)
22. Choy H, Devore RW 3rd, Hande KR et al (2000) A phase II study of paclitaxel, carboplatin and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network study). Int J Radiat Oncol Biol Phys 47:931-937 (Pubitemid 30345590)
23. Qiao WB, Zhao YH, Zhao YB, Wang RZ (2005) Clinical and dosimetric factors of radiation-induced esophageal injury: radiation-induced esophageal toxicity. World J Gastroenterol 11:2626-2629
24. Yom S, Liao Z, Liu H et al (2007) Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68:94-102 (Pubitemid 46589835)
25. Jeremic B, Milicic M, Dagovic A, Aleksandrovic J, Milisavljevic S (2004) Interfraction interval in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy. Final results in 536 patients. Am J Clin Oncol 27:616-625 (Pubitemid 39603278)
26. Robnett TJ, Machtay M, Vines EF, McKenna MG, Algazy KM, McKenna WG (2000) Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 48:89-94 (Pubitemid 30488217)
27. Rancati T, Ceresoli GL, Gagliardi G, Schipani S, Cattaneo GM (2003) Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 67:275-283 (Pubitemid 36831080)
28. Inoue A, Kunitoh H, Sekine, Sumi M, Tokuuye K, Saijo N (2001) Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 49:649-655 (Pubitemid 32114101)
29. Hernando ML, Marks LB, Bentel GC et al (2001) Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51:650-659
30. Yamada M, Kudoh S, Hirata K, Nakajima T, Yoshikawa J (1998) Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 34:71-75
31. Singh AK, Lockett MA, Bradley JD (2003) Predictors of radiation induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 55:337-341 (Pubitemid 36069091)
32. Werner-Wasik M, Pequignot E, Leeper D, Hauck W, Curran W (2000) Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer with nonoperative therapy. Int J Radiat Oncol Biol Phys 48:689-696
33. Moreno M, Aristu J, Ramos LI et al (2007) Predictive factors for radiationinduced pulmonary toxicity after three-dimensional conformal chemoradiation in locally advanced non-small-cell lung cancer. Clin Transl Oncol 9:596-602
34. De Petris L, Lax I, Sirzén F, Friesland S (2005) Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer. Med Oncol 22:375-381 (Pubitemid 43780294)
35. Roach M III, Gandara DR, Yuo HS et al (1995) Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 13:2606-2612
36. Bese N, Hendry J, Jeremić B (2007) Effects of prolongation of the overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensations. Int J Radiat Oncol Biol Phys 68:654-661 (Pubitemid 46818766)
37. Jeremić B, Miličić B, Milisavljevic S (2011) Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-smallcell lung cancer: single institution experience with 600 patients. Int J Radiat Oncol Biol Phys (in press)
38. Jeremić B, Miličić B, Milisavljevic S (2011) Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-institution experience in 600 patients. Cancer 117:2995-3003